Descriptors
Documents disponibles dans cette catégorie (44)
Add the result to your basket Make a suggestion Refine your search Apply to external sourcesExtend search on down-posting(s)
21st Cochrane Colloquium / Oxford [UK] : The Cochrane Collaboration (2013)
21st Cochrane Colloquium
Quebec ; 19-23 September 2013
Languages : English (eng) French (fre)
Descriptors: Classification
W 3 Congresses
Indexation
Congresses ; Decision Making ; Evidence-Based Medicine ; Evidence-Based Practice ; Health Care ; Health Knowledge, Attitudes, Practice ; Societies, ScientificAbstract: The focus of this year’s Colloquium: Better Knowledge for Better Health|Un meilleur savoir pour une meilleure santé is on how evidence informs health care decisions at every level – from patient to practitioner, to institutional or government policy-maker.
Plenary sessions will feature international experts addressing the following topics:
20 years of better knowledge for better health
Better knowledge for better health: decision-makers’ perspectives
Better knowledge for better health: global health and equity perspectives
The next 20 years of better knowledge
In addition, we will offer special sessions on specific topics, including:
Wikipedia and transferring health information
Patients, evidence production and its use
Evidence for policy-makers
The ‘French Connection’: the work of Cochrane for francophones
Systematic reviews and guideline development
Better Knowledge for Better Health|Un meilleur savoir pour une meilleure santé will commence on Friday, 20 September 2013 with the opening ceremony and first plenary session and end on Monday, 23 September. In addition to an excellent scientific program, we will offer a superb social program with opportunities to network and meet new and existing colleagues from around the world. Please note the Welcome Reception will take place on the evening of Thursday, 19 September.Link for e-copy: http://ccc.cochrane.org/ Format of e-copy: Web site Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=3627 Copies
Barcode Call number Media type Location Section Status No copy
ISBN : 978-0-309-21435-3 : $ 72,86
Languages : English (eng)
Descriptors: Indexation
Electronic books ; Encephalitis, Varicella Zoster ; Epidemiology ; Evidence-Based Practice ; Influenza Vaccines ; Papillomavirus Vaccines ; United States ; Vaccines
Classification
QW 805 Vaccines. Antitoxins. ToxoidsAbstract:
In 1900, for every 1000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The cornerstone of the vaccine safety system in the United States is the National Childhood Vaccine Injury Act. This legislation was intended to bolster vaccine research and development through federal coordination of vaccine initiatives, and by providing relief to vaccine manufacturers facing financial burdens. A key component of the legislation required the Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse effects, especially in children.
The Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health effects associated with specific vaccines covered by the Vaccine Injury Compensation Program including varicella zoster vaccine, influenza vaccines, hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews prior studies, summarizes their findings, and evaluates the epidemiological evidence. It finds that while no vaccine is 100% safe, very few adverse events are shown to be caused by vaccines.
In addition, the evidence shows that vaccines do not cause several conditions of recent concern. For example, the MMR vaccine is not associated with autism or childhood diabetes. The DTaP vaccine is also not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. The Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors.Contents note:
SUMMARY 1 -- Charge to the Committee 2 -- Assessing the Weight of Evidence 2 -- Causality Assessment 5 -- Causality Conclusions 7 -- Susceptibility 9 -- Concluding Comment 9 -- References 24 -- 1 INTRODUCTION 25 -- Charge to the Committee 27 -- Committee Process 28 -- Outline of the Report 28 -- References 33 -- 2 APPROACH 35 -- Literature Searching 35 -- Weight of Evidence 36 -- Causality Assessment 41 -- Special Considerations 45 -- References 48 -- 3 EVALUATING BIOLOGICAL MECHANISMS OF ADVERSE EVENTS 51 -- Latency Between Antigen Exposure and Peak Adaptive Immune Response 51 -- Immune-Mediated Mechanisms 52 -- Viral Activity 66 -- Injection-Related Adverse Events 67 -- Coagulation and Hypercoagulable States 69 -- Increased Susceptibility 70 -- Alterations in Brain Development 73 -- Contribution of Animal Models 76 -- References 79 -- 4 MEASLES, MUMPS, AND RUBELLA VACCINE 89 -- Introduction 89 -- Measles Inclusion Body Encephalitis 93 -- Encephalitis and Encephalopathy 95 -- Febrile Seizures 100 -- Afebrile Seizures 105 -- Meningitis 107 -- Ataxia 110 -- Autism 112 -- Acute Disseminated Encephalomyelitis 115 -- Transverse Myelitis 116 -- Optic Neuritis 117 -- Neuromyelitis Optica 119 -- Multiple Sclerosis Onset in Adults 120 -- Multiple Sclerosis Onset in Children 122 -- Guillain-Barré Syndrome 123 -- Chronic Inflammatory Disseminated Polyneuropathy 124 -- Opsoclonus Myoclonus Syndrome 125 -- Brachial Neuritis 125 -- Anaphylaxis 126 -- Transient Arthralgia in Women 130 -- Transient Arthralgia in Children 134 -- Chronic Arthralgia in Women 137 -- Chronic Arthritis in Women 140 -- Chronic Arthropathy in Children 143 -- Arthropathy in Men 144 -- Type 1 Diabetes 146 -- Hepatitis 149 -- Chronic Fatigue Syndrome 150 -- Fibromyalgia 151 -- Hearing Loss 151 -- References 196 -- 5 VARICELLA VIRUS VACCINE 211 -- Introduction 211 -- Disseminated Oka VZV Without Other Organ Involvement 213 -- Disseminated Oka VZV with Other Organ Involvement 219 -- Vaccine Strain Viral Reactivation Without Other Organ Involvement 224 -- Vaccine Strain Viral Reactivation with Other Organ Involvement 228 -- Encephalopathy 233 -- Seizures 233 -- Cerebellar Ataxia 235 -- Acute Disseminated Encephalomyelitis 236 -- Transverse Myelitis 237 -- Guillain-Barré Syndrome 238 -- Small Fiber Neuropathy 239 -- Anaphylaxis 239 -- Onset or Exacerbation of Arthropathy 242 -- Stroke 243 -- Thrombocytopenia 244 -- References 248 -- 6 INFLUENZA VACCINE 257 -- Introduction 257 -- Encephalitis and Encephalopathy 262 -- Seizures 264 -- Acute Disseminated Encephalomyelitis 267 -- Optic Neuritis 269 -- Neuromyelitis Optica 271 -- Multiple Sclerosis Onset in Adults 271 -- Multiple Sclerosis Relapse in Adults 273 -- Guillain-Barré Syndrome 275 -- Chronic Inflammatory Disseminated Polyneuropathy 281 -- Bell’s Palsy 282 -- Brachial Neuritis 284 -- Small Fiber Neuropathy 285 -- Anaphylaxis 285 -- Inactivated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children and Adults 288 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children Younger Than 5 Years of Age 293 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Persons 5 Years of Age or Older 298 -- Onset or Exacerbation of Systemic Lupus Erythematosus 301 -- Onset or Exacerbation of Vasculitis 304 -- Polyarteritis Nodosa 306 -- Onset or Exacerbation of Arthropathy 307 -- Stroke 308 -- Myocardial Infarction 309 -- Fibromyalgia 311 -- All-Cause Mortality 311 -- Oculorespiratory Syndrome 313 -- References 354 -- 7 HEPATITIS A VACCINE 369 -- Introduction 369 -- Acute Disseminated Encephalomyelitis 370 -- Transverse Myelitis 371 -- Multiple Sclerosis 372 -- Guillain-Barré Syndrome 373 -- Chronic Inflammatory Disseminated Polyneuropathy 374 -- Bell’s Palsy 374 -- Anaphylaxis 375 -- Autoimmune Hepatitis 376 -- References 378 -- 8 HEPATITIS B VACCINE 381 -- Introduction 381 -- Encephalitis and Encephalopathy 383 -- Seizures 383 -- Acute Disseminated Encephalomyelitis 385 -- Transverse Myelitis 386 -- Optic Neuritis 387 -- Neuromyelitis Optica 389 -- Multiple Sclerosis Onset in Adults 390 -- Multiple Sclerosis Onset in Children 392 -- Multiple Sclerosis Relapse in Adults 394 -- Multiple Sclerosis Relapse in Children 395 -- First Demyelinating Event in Adults 396 -- First Demyelinating Event in Children 399 -- Guillain-Barré Syndrome 400 -- Chronic Inflammatory Disseminated Polyneuropathy 401 -- Brachial Neuritis 402 -- Anaphylaxis 402 -- Erythema Nodosum 403 -- Onset or Exacerbation of Systemic Lupus Erythematosus 404 -- Onset or Exacerbation of Vasculitis 406 -- Onset or Exacerbation of Polyarteritis Nodosa 409 -- Onset or Exacerbation of Psoriatic Arthritis 411 -- Onset or Exacerbation of Reactive Arthritis 412 -- Onset or Exacerbation of Rheumatoid Arthritis 414 -- Onset or Exacerbation of Juvenile Idiopathic Arthritis 416 -- Type 1 Diabetes 418 -- Fibromyalgia 420 -- References 431 -- 9 HUMAN PAPILLOMAVIRUS VACCINE 441 -- Introduction 441 -- Acute Disseminated Encephalomyelitis 442 -- Transverse Myelitis 443 -- Neuromyelitis Optica 444 -- Multiple Sclerosis 444 -- Guillain-Barré Syndrome 445 -- Chronic Inflammatory Disseminated Polyneuropathy 446 -- Brachial Neuritis 447 -- Amyotrophic Lateral Sclerosis 447 -- Anaphylaxis 449 -- Transient Arthralgia 450 -- Pancreatitis 451 -- Thromboembolic Events 452 -- Hypercoagulable States 453 -- References 455 -- 10 DIPHTHERIA TOXOID-, TETANUS TOXOID-, AND ACELLULAR PERTUSSISCONTAINING -- VACCINES 457 -- Introduction 457 -- Encephalitis and Encephalopathy 461 -- Infantile Spasms 464 -- Seizures 465 -- Ataxia 468 -- Autism 468 -- Acute Disseminated Encephalomyelitis 469 -- Transverse Myelitis 470 -- Optic Neuritis 471 -- Multiple Sclerosis Onset in Adults 472 -- Multiple Sclerosis Relapse in Adults 474 -- Multiple Sclerosis Relapse in Children 476 -- Guillain-Barré Syndrome 477 -- Chronic Inflammatory Disseminated Polyneuropathy 478 -- Opsoclonus Myoclonus Syndrome 480 -- Bell’s Palsy 480 -- Anaphylaxis 482 -- Chronic Urticaria 483 -- Serum Sickness 484 -- Arthropathy 485 -- Type 1 Diabetes 487 -- Myocarditis 490 -- Fibromyalgia 491 -- Sudden Infant Death Syndrome 491 -- Immune Thrombocytopenic Purpura 492 -- References 506 -- 11 MENINGOCOCCAL VACCINE 515 -- Introduction 515 -- Encephalitis and Encephalopathy 517 -- Acute Disseminated Encephalomyelitis 518 -- Transverse Myelitis 519 -- Multiple Sclerosis 519 -- Guillain-Barré Syndrome 520 -- Chronic Inflammatory Disseminated Polyneuropathy 521 -- Anaphylaxis 522 -- Chronic Headache 523 -- References 526 -- 12 INJECTION-RELATED ADVERSE EVENTS 529 -- Complex Regional Pain Syndrome 529 -- Deltoid Bursitis 531 -- Syncope 533 -- References 538 -- 13 CONCLUDING COMMENTS 541 -- References 545Link for e-copy: http://www.nap.edu/catalog.php?record_id=13164 Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2712
ISSN : D/2010/10.273/67 : € 0,00
Study n. : 2009-22
Languages : English (eng)
Descriptors: Indexation
2009-22 ; Cardiac rehabilitation ; Evidence-Based Practice ; Health Services Accessibility ; Health Services Needs and Demand ; R140 ; Rehabilitation centers
Classification
WG 166 Cardiovascular Diseases, Diagnosis and Therapeutics -- TherapeuticsContents note: GLOSSARY 3 -- 1 BACKGROUND AND RESEARCH QUESTIONS 4 -- 1.1 BACKGROUND 4 -- 1.1.1 Cardiac rehabilitation 4 -- 1.1.2 Different approaches to cardiac rehabilitation 4 -- 1.1.3 Heart disease and treatment goals 4 -- 1.1.4 Organisation of multidisciplinary cardiac rehabilitation in Belgium 5 -- 1.1.5 Treatment access 5 -- 1.2 RESEARCH QUESTIONS 6 -- 1.3 PARTS OF THE STUDY 6 -- 2 SYSTEMATIC LITERATURE REVIEW 7 -- 2.1 RESEARCH QUESTION 7 -- 2.2 METHODS 7 -- 2.2.1 Selection of studies 7 -- 2.2.2 Project Outline 8 -- 2.2.3 Literature search strategy 9 -- 2.2.4 Assessing methodological quality and risk of bias 9 -- 2.2.5 Data extraction 10 -- 2.3 RESULTS 10 -- 2.3.1 Phase I: systematic reviews and meta-analyses 10 -- 2.3.2 Phase II: original RCTs 17 -- 2.3.3 Multidisciplinary cardiac rehabilitation versus exercise 22 -- 2.4 HTA DOCUMENTS 22 -- 2.5 SUMMARY OF RESULTS AND DISCUSSION 24 -- 2.5.1 Summary of results 24 -- 2.5.2 Additional Cochrane reviews published in 2010 25 -- 2.5.3 Discussion of results 26 -- 2.5.4 Systematic review of the economic literature 27 -- 2.5.5 Comparison of the current results with guidance documents 28 -- 3 REHABILITATION AFTER DEFINED CARDIAC PROCEDURES IN BELGIUM: -- DATA ANALYSIS 32 -- 3.1 METHODOLOGY 32 -- 3.1.1 Data source 32 -- 3.1.2 Study period and observation period 32 -- 3.1.3 Target population and patient selection procedure 33 -- 3.1.4 Data collection 34 -- 3.1.5 Patient classification 35 -- 3.1.6 Data analysis 38 -- 3.2 RESULTS 39 -- 3.2.1 Patients selected for analysis. 39 -- 3.2.2 Patient Geographical Spread 40 -- 3.2.3 Type of Rehabilitation 41 -- 3.2.4 Rehabilitation related data 45 -- 3.2.5 Utilisation of rehabilitation types per socio-demographic patient characteristics 53 -- 3.2.6 Cardiac centre related data 60 -- 3.2.7 Multivariate analysis 61 -- 3.2.8 Cardiac disease related resource use: outpatient visits and diagnostic tests 65 -- 3.3 SUMMARY AND LIMITATIONS 69 -- 3.3.1 Summary of the descriptive statistics 69 -- 3.3.2 Summary of the multivariate analyses 70 -- 3.3.3 Strengths and limitations of the data analysis 70 -- 4 PATIENT SURVEY 71 -- 4.1 METHODOLOGY 71 -- 4.1.1 Study design 71 -- 4.1.2 Study population 71 -- 4.1.3 Time horizon 71 -- 4.1.4 Patient recruitment 72 -- 4.1.5 Data management & privacy 72 -- 4.1.6 Data collection 72 -- 4.1.7 Data analysis 73 -- 4.2 RESULTS 74 -- 4.2.1 Cardiologists 74 -- 4.2.2 Characteristics of the patients. 74 -- 4.2.3 Participation to the cardiac rehabilitation programme 75 -- 4.3 SUMMARY OF RESULTS AND LIMITATIONS OF THE SURVEY 86 -- 4.3.1 Main results 86 -- 4.3.2 Limitations of the survey 87 -- 5 GENERAL DISCUSSION AND CONCLUSIONS 88 -- 5.1 DEFINITIONS OF MULTIDISCIPLINARY REHABILITATION 88 -- 5.2 EVIDENCE ABOUT EXERCISE AND MULTIDISCIPLINARY CARDIAC REHABILITATION -- INCLUDING EXERCISE 88 -- 5.3 LACK OF PRECISION ABOUT TARGET POPULATIONS AND OTHER FEATURES OF -- CARDIAC REHABILITATION 89 -- 5.4 PARTICIPATION IN REHABILITATION PROGRAMMES IN BELGIUM 89 -- 5.4.1 Influence of patient characteristics 89 -- 5.4.2 Other factors that influence the participation in cardiac rehabilitation programmes 91 -- 5.4.3 Limits in the comparison between this study and the data from the literature 91 -- 6 REFERENCES 93 Link for e-copy: https://doi.org/10.57598/R140C Format of e-copy: PDF (2,43 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2217 Copies
Barcode Call number Media type Location Section Status No copy
ISSN : D/2010/10.273/68 : € 0,00
Study n. : 2009-22
Languages : English (eng)
Descriptors: Indexation
2009-22 ; Cardiac rehabilitation ; Evidence-Based Practice ; Health Services Accessibility ; Health Services Needs and Demand ; R140 ; Rehabilitation centers
Classification
WG 166 Cardiovascular Diseases, Diagnosis and Therapeutics -- TherapeuticsContents note: GLOSSARY 2 -- 1 APPENDICES SYSTEMATIC LITERATURE REVIEW 3 -- Appendix 1: systematic review Search strategy 3 -- Appendix 2: RCT Search strategy 10 -- Appendix 3: INAHTA member websites searched 17 -- 2 APPENDICES: ANALYSIS OF IMA DATABASE 79 -- Appendix 1: Nomenclature codes used for patient classification 79 -- Appendix 2: Description of patient inclusion and exclusion 85 -- appendix 3: Rehabilitation sequences 86 -- Appendix 4 rehabilitation related data during the entire one-year observation period 87 -- Appendix 5: cost related to rehabilitation 91 -- Appendix 6 socio-demographic patient characteristics 98 -- Appendix 7 Geographical spread of patients in outpatient rehabilitation 99 -- Appendix 8 Cardiac disease related medical care consumption 103 -- Appendix 9: Multivariate analysis 107 -- 3 APPENDIX : SURVEY 109 -- Patient Survey questionnaires 109 -- List of participating hospitals/centres 117 -- Participating cardiologists 117 -- Details on patients’ characteristics 118 -- Details on the participation to the rehabilitation programme 121 Link for e-copy: https://doi.org/10.57598/R140S Format of e-copy: PDF (1,18 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2218 Copies
Barcode Call number Media type Location Section Status No copy
ISSN : D/2010/10.273/65 : € 0,00
Studie nr : 2009-22
Languages : English (eng) Dutch (nla)
Descriptors: Indexation
2009-22 ; Cardiac rehabilitation ; Evidence-Based Practice ; Health Services Accessibility ; Health Services Needs and Demand ; R140 ; Rehabilitation centers
Classification
WG 166 Cardiovascular Diseases, Diagnosis and Therapeutics -- TherapeuticsAbstract: Hartrevalidatie met lichamelijke oefeningen heeft een gunstig effect op de levenskwaliteit van hartpatiënten en vermindert het aantal hospitalisaties en overlijdens. Dit is een belangrijke conclusie van een studie van het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) en Deloitte®. Toch volgt minder dan een op 2 hartpatiënten revalidatie na hospitalisatie. Vooral ouderen en vrouwen dreigen uit de boot te vallen. Als belangrijkste redenen vermelden ze tijdsgebrek, het idee dat ze ook wel zonder deze behandeling zullen genezen, de afstand tot een erkend revalidatiecentrum en het gebrek aan transportmiddelen. Het KCE pleit voor de ontwikkeling van individueel aangepaste oefen- en begeleidingsprogramma’s bij het ontslag uit het ziekenhuis, gespreid over verschillende maanden en dichtbij de woonplaats van de patiënt. Contents note: GLOSSARY 3 -- 1 BACKGROUND AND RESEARCH QUESTIONS 4 -- 1.1 BACKGROUND 4 -- 1.1.1 Cardiac rehabilitation 4 -- 1.1.2 Different approaches to cardiac rehabilitation 4 -- 1.1.3 Heart disease and treatment goals 4 -- 1.1.4 Organisation of multidisciplinary cardiac rehabilitation in Belgium 5 -- 1.1.5 Treatment access 5 -- 1.2 RESEARCH QUESTIONS 6 -- 1.3 PARTS OF THE STUDY 6 -- 2 SYSTEMATIC LITERATURE REVIEW 7 -- 2.1 RESEARCH QUESTION 7 -- 2.2 METHODS 7 -- 2.2.1 Selection of studies 7 -- 2.2.2 Project Outline 8 -- 2.2.3 Literature search strategy 9 -- 2.2.4 Assessing methodological quality and risk of bias 9 -- 2.2.5 Data extraction 10 -- 2.3 RESULTS 10 -- 2.3.1 Phase I: systematic reviews and meta-analyses 10 -- 2.3.2 Phase II: original RCTs 17 -- 2.3.3 Multidisciplinary cardiac rehabilitation versus exercise 22 -- 2.4 HTA DOCUMENTS 22 -- 2.5 SUMMARY OF RESULTS AND DISCUSSION 24 -- 2.5.1 Summary of results 24 -- 2.5.2 Additional Cochrane reviews published in 2010 25 -- 2.5.3 Discussion of results 26 -- 2.5.4 Systematic review of the economic literature 27 -- 2.5.5 Comparison of the current results with guidance documents 28 -- 3 REHABILITATION AFTER DEFINED CARDIAC PROCEDURES IN BELGIUM: -- DATA ANALYSIS 32 -- 3.1 METHODOLOGY 32 -- 3.1.1 Data source 32 -- 3.1.2 Study period and observation period 32 -- 3.1.3 Target population and patient selection procedure 33 -- 3.1.4 Data collection 34 -- 3.1.5 Patient classification 35 -- 3.1.6 Data analysis 38 -- 3.2 RESULTS 39 -- 3.2.1 Patients selected for analysis. 39 -- 3.2.2 Patient Geographical Spread 40 -- 3.2.3 Type of Rehabilitation 41 -- 3.2.4 Rehabilitation related data 45 -- 3.2.5 Utilisation of rehabilitation types per socio-demographic patient characteristics 53 -- 3.2.6 Cardiac centre related data 60 -- 3.2.7 Multivariate analysis 61 -- 3.2.8 Cardiac disease related resource use: outpatient visits and diagnostic tests 65 -- 3.3 SUMMARY AND LIMITATIONS 69 -- 3.3.1 Summary of the descriptive statistics 69 -- 3.3.2 Summary of the multivariate analyses 70 -- 3.3.3 Strengths and limitations of the data analysis 70 -- 4 PATIENT SURVEY 71 -- 4.1 METHODOLOGY 71 -- 4.1.1 Study design 71 -- 4.1.2 Study population 71 -- 4.1.3 Time horizon 71 -- 4.1.4 Patient recruitment 72 -- 4.1.5 Data management & privacy 72 -- 4.1.6 Data collection 72 -- 4.1.7 Data analysis 73 -- 4.2 RESULTS 74 -- 4.2.1 Cardiologists 74 -- 4.2.2 Characteristics of the patients. 74 -- 4.2.3 Participation to the cardiac rehabilitation programme 75 -- 4.3 SUMMARY OF RESULTS AND LIMITATIONS OF THE SURVEY 86 -- 4.3.1 Main results 86 -- 4.3.2 Limitations of the survey 87 -- 5 GENERAL DISCUSSION AND CONCLUSIONS 88 -- 5.1 DEFINITIONS OF MULTIDISCIPLINARY REHABILITATION 88 -- 5.2 EVIDENCE ABOUT EXERCISE AND MULTIDISCIPLINARY CARDIAC REHABILITATION -- INCLUDING EXERCISE 88 -- 5.3 LACK OF PRECISION ABOUT TARGET POPULATIONS AND OTHER FEATURES OF -- CARDIAC REHABILITATION 89 -- 5.4 PARTICIPATION IN REHABILITATION PROGRAMMES IN BELGIUM 89 -- 5.4.1 Influence of patient characteristics 89 -- 5.4.2 Other factors that influence the participation in cardiac rehabilitation programmes 91 -- 5.4.3 Limits in the comparison between this study and the data from the literature 91 -- 6 REFERENCES 93 Link for e-copy: https://doi.org/10.57598/R140A Format of e-copy: PDF (2,33 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2216 Copies
Barcode Call number Media type Location Section Status No copy
PermalinkConsort / Consort Group (2010)
Permalink
Permalink
Permalink
Permalink
Permalink
PermalinkPermalink
Permalink
Permalink
